Williamstown, MA -- (SBWIRE) -- 04/17/2012 -- GBI Research, the leading business intelligence provider, has released its latest research, "Endpoints - Clinical Trials in Autoimmune Disorders - Multiple Primary and Secondary Endpoints are Increasingly Being Applied to Ensure Success" which provides an insight into different endpoints used in clinical trials in autoimmune disorders. The report examines different aspects of clinical trial endpoints in autoimmune disorders, such as analysis of major marketed autoimmune drugs with an emphasis on safety and efficacy details, Phase II and Phase III clinical trial analysis for both completed and ongoing clinical trials, most promising autoimmune drugs, and terminated trial analysis. The company profiles highlight the autoimmune drugs of different companies.
View Full Report Details and Table of Contents
Autoimmune disorders represent a collective group of disorders which primarily arise due to an overactive immune response of the body against substances and tissues normally present within the body. Most of them cause significant morbidity and disability and are very difficult to diagnose. The cause of autoimmune diseases remains unknown, although genetic factors play a major role in susceptibility. Some of the autoimmune diseases may be triggered by environmental exposure or by an infectious agent. They can attack any tissue or organ of the body and cause a wide range of symptoms and organ injuries, depending on the site of immune attack.
This report details "Endpoints - Clinical Trials in Autoimmune Disorders", highlighting the five major autoimmune disorders of multiple sclerosis, rheumatoid arthritis, Crohn's disease, ulcerative colitis and psoriasis. The classification of five major autoimmune diseases is based on the number of pipeline molecules present in the Phase III stage of development.
The term endpoint refers to an outcome or measure of a clinical trial. Endpoints can include all kinds of aspects, those related to the effectiveness of treatment and others. However, the endpoint selection must take into account the need to obtain the information of the highest therapeutic interest with the least risk and discomfort for the individual. Also, the endpoints must be aligned with the objectives of the study and represent the most effective way to assess pharmacological response.
This report details the clinical trial endpoints in autoimmune disorders. The report covers -
- Data and analysis on the marketed products and analysis of their efficacy and safety details
- Analysis of the five major autoimmune diseases: Multiple sclerosis, rheumatoid arthritis, Crohn's disease, ulcerative colitis and psoriasis.
Companies Mentioned in this Report: Biogen Idec Inc, Amgen Inc, Johnson & Johnson, Teva Pharmaceutical Industries Limited, Shire Plc, F. Hoffmann-La Roche Ltd, Merck KGaA
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- Endpoints - Clinical Trials in Cardiovascular Disorders - Optimal Use of Surrogate Endpoints and Clinical Biomarkers are Key Determinants of Success
- Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and Ratings Scales are Becoming More Widely Adopted
- Endpoints - Clinical Trials in Dermatology - Inflammatory Lesions Count is the Key Determinant of Success in Acne Vulgaris Clinical Trials
- Endpoints - Clinical Trials in Orphan Diseases - Highest Number of Terminated Trials Focused on Mulitiple Myeloma
- Clinical Trial Recruitment in Autoimmune Disorders-Average Patient Recruitment Per Trial has Continued to Decline Over the Past Decade
- Clinical Trial Endpoints in Oncology - Inclusion of Surrogate Endpoints and Shorter Endpoints Will Ensure Faster Clinical Trials in Oncology
- Trends in Clinical Trials: Strategies to enhance clinical trial design
- Clinical Trial Recruitment in Orphan Diseases - Patient Numbers in Ovarian Cancer Trials Exceed Other Orphan Diseases in Oncology
- Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic gastrointestinal cancers represent a significant commercial opportunity due to a lack of approved drugs
- Leukocyte Disorders (White Blood Cell Disorders) Global Clinical Trials Review, Q4, 2010